WST
West Pharmaceutical ServicesQuote snapshot (US/Eastern): Jul 24, 2026, 4:01 PM. Quotes are indicative and may be delayed. Not investment advice. Disclaimer & sources
West Pharmaceutical Services is a leading company in the Healthcare sector with a current dividend yield of 0.24%. It has increased its dividend for 52 consecutive years, recognized as a Dividend King in our classification. The next ex-dividend date is scheduled for 2026-08-05.
Similar Healthcare dividend stocks
Frequently Asked Questions about West Pharmaceutical Services
Q. What is the current dividend yield of West Pharmaceutical Services (WST)?
A. The current dividend yield of West Pharmaceutical Services is 0.24%.
Q. How many years has West Pharmaceutical Services increased its dividend?
A. West Pharmaceutical Services has increased its dividend for 52 consecutive years, making it a Dividend King.
Q. What is the dividend safety score for West Pharmaceutical Services?
A. Based on our analysis, West Pharmaceutical Services has a dividend safety score of 100 out of 100.
Q. What sector does West Pharmaceutical Services operate in?
A. West Pharmaceutical Services operates in the Healthcare sector.
Top dividend ETFs holding WST
Among the dividend ETFs featured on this site, these reported the largest portfolio weight in this stock (Yahoo Finance top holdings; figures may lag or change).
| ETF | Portfolio weight |
|---|---|
| NOBL ProShares S&P 500 Dividend Aristocrats | 1.83% |
WST News
Latest headlines for this stock from our dividend news archive (up to 20).
West Pharmaceutical (WST) Signs Decade Long Daikyo Distribution Deal Beyond Japan
WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook
West Pharmaceutical Services (WST) Expands Daikyo Ties As Valuation Questions Grow
West Pharmaceutical Services (WST) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
Veeva Acquires Copli & Launches Falcon MLR for Faster Content Reviews
RDNT's Unit DeepHealth Expands AI Breast Suite With FDA-Cleared Tools
Headlines are in the original language. Links open the source publisher.